The National Health Service (NHS) has prescribed Novo Nordisk A/S’s (NYSE:NVO) weight-loss drug Wegovy far less often than anticipated, struggling with a shortage of weight management clinics required to distribute the popular treatment. Since its launch, the drug has been prescribed just 3,300 times, significantly below the 13,500 patients expected to receive it in its first year, according to a Financial Times analysis of NHS England data. Demand for Wegovy is set to increase following the Medicines and Healthcare Products Regulatory Agency’s (MHRA) approval for its use in reducing the risk of serious heart problems or strokes in overweight and obese adults. Despite this, the drug is in short supply internationally. The NHS has prioritized supplies of Ozempic, another drug by Novo ...